Conferences

July 16, 2024

Dr. Pierre Bories shared research findings about similarities and differences between older and younger DLBCL patients treated with CAR T-cell therapy.

July 15, 2024

The bispecific antibody epcoritamab (Epkinly) was recently FDA-approved for the treatment of relapsed/refractory follicular lymphoma. Find out more!

July 09, 2024

First results of golcadomide, a new CELMoD, in monotherapy and with rituximab relapsed/refractory follicular lymphoma (non-Hodgkin Lymphoma) by Dr. Chavez.

June 13, 2024

Dr. Jeong Kim shares findings about how the treatment combination of brentuximab vedotin, lenalidomide, and rituximab helps R/R DLBCL patients.

May 27, 2024

The American Society of Clinical Oncology holds a yearly conference in June to allow researchers and doctors in the cancer community an opportunity to share…

May 27, 2024

The American Society of Clinical Oncology holds a yearly conference in June to allow researchers and doctors in the cancer community an opportunity to share…

May 06, 2024

Discover Evorpacept: A Next-Generation CD47 Checkpoint Inhibitor For Cancer Treatment with Enhanced Safety and Efficacy.

March 13, 2024

A scientific talk at Tandem 2024 in San Antonio, debates CAR T-cell vs. bispecific antibody therapies for R/R Diffuse Large B-cell Lymphoma.

March 11, 2024

Dr. Nnawub shared research about how the type of insurance a patient has impacts their survival outcomes and the quality of care they receive.

March 11, 2024

Dr. Nnawub shared research about how the type of insurance a patient has impacts their survival outcomes and the quality of care they receive.